Biomarker Clinical Phase Outsourcing Services Market, 2033

The new report published by The Business Research Company, titled ""Biomarker Clinical Phase Outsourcing Services Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the biomarker clinical phase outsourcing services market size has grown exponentially in recent years. It will grow from $7.91 billion in 2023 to $9.71 billion in 2024 at a compound annual growth rate (CAGR) of 22.7%. The biomarker clinical phase outsourcing services market size is expected to see exponential growth in the next few years. It will grow to $22.09 billion in 2028 at a compound annual growth rate (CAGR) of 22.8%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp

Expanding Clinical Trial Landscape Fuels Growth Of Biomarker Clinical Phase Outsourcing Services Market
The rise in clinical trials is expected to propel the growth of the biomarker clinical phase outsourcing services market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The surge in clinical trials is facilitated by advancements in medical research, rising prevalence of chronic diseases, increased funding from both governmental and private sources, and the growing demand for innovative treatments and therapies. Outsourcing providers often have specialized knowledge and experience in biomarker discovery, validation, and analysis. This expertise can enhance the quality and reliability of the biomarker data collected during the trial. For instance, in May 2023, according to the United States National Library of Medicine, registered clinical trials increased from 399,499 in 2022 to 437,533 in all 50 states and across 221 countries. Furthermore, it was reported that 140,492 studies (31%) are registered in the United States only, whereas 241,498 studies (53%) are recorded in non-U.S. locations. Therefore, the rise in clinical trials will drive the growth in the biomarker clinical phase outsourcing services market forward.

Advancements Drive Competition In Biomarker Clinical Phase Outsourcing Services
Major companies in the biomarker clinical phase outsourcing services are focusing on advancements with high-throughput flow cytometry and ELISpot testing to gain a competitive edge in the market. High-throughput flow cytometry and ELISpot testing are utilized for biomarker analysis, offering rapid and precise assessment of immune responses and cellular markers. For instance, in November 2022, Celerion Inc., a US-based biotechnology outsourcing services company, expanded its service offering to include GLP/GCP-compliant molecular and cell biology testing. This strategic move aims to enhance Celerion's capabilities in supporting clients throughout the drug development process, from early clinical research to regulatory submissions. Celerion can provide a more comprehensive range of services by adding GLP/GCP-compliant molecular and cell biology tests, such as pharmacokinetic (PK), pharmacodynamic (PD), and biomarker analysis. This expansion enables Celerion to assist clients in producing high-quality data that meets regulatory requirements, thereby speeding up the development of new medicines.

The biomarker clinical phase outsourcing services market covered in this report is segmented -

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types
2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis
3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas
4) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutions

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=15740&type=discount

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Intertek Group plc, Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Bioclinica Inc., Evotec SE, GenScript Biotech Corporation, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Selvita S.A., BioIVT LLC, Discovery Life Sciences LLC, Metabolon Inc., Caprion Proteomics Inc., Canopy Biosciences LLC

Contents of the report:
1. Executive Summary
2. Biomarker Clinical Phase Outsourcing Services Market Report Structure
3. Biomarker Clinical Phase Outsourcing Services Market Trends And Strategies
4. Biomarker Clinical Phase Outsourcing Services Market - Macro Economic Scenario
5. Biomarker Clinical Phase Outsourcing Services Market Size And Growth
…..
27. Biomarker Clinical Phase Outsourcing Services Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company

The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.